EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal

Hannah D West, Mark Nellist iD, Rutger W W Brouwer, Mirjam C G N van den Hout-van Vroonhoven, Luiz Gustavo Dufner de Almeida, Femke Hendriks, Peter Elfferich, Meera Raja, Peter Giles, Rosa M Alfano, Angela Peron, Yves Sznajer und 9 weitere

Human Mutation · 2023

DOI: 10.1155/2023/4899372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2023. Verfasst von Hannah D West und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK. Hauptthemen laut MEDLINE: Tuberous Sclerosis Complex 2 Protein, Tuberous Sclerosis, Tuberous Sclerosis Complex 1 Protein. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Care Research Wales, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, TS Association UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberous sclerosis complex (TSC) is caused by inactivating variants in TSC1 and TSC2. Somatic mosaicism, as well as the size and complexity of the TSC1 and TSC2 loci, makes variant identification challenging. Indeed, in some individuals with a clinical diagnosis of TSC, diagnostic testing fails to identify an inactivating variant. To improve TSC1 and TSC2 variant detection, we screened the TSC1 and TSC2 genomic regions using targeted HaloPlex custom capture and next-generation sequencing (NGS) in genomic DNA isolated from peripheral blood of individuals with definite, possible or suspected TSC in whom no disease-associated variant had been identified by previous diagnostic genetic testing. We obtained >95% target region coverage at a read depth of 20 and >50% coverage at a read depth of 300 and identified inactivating TSC1 or TSC2 variants in 83/155 individuals (54%); 65/113 (58%) with clinically definite TSC and 18/42 (43%) with possible or suspected TSC. These included 19 individuals with deep intronic variants and 54 likely cases of mosaicism (variant allele frequency 1-28%; median 7%). In 13 cases (8%), we identified a variant of uncertain significance (VUS). Targeted genomic NGS of TSC1 and TSC2 increases the yield of inactivating variants found in individuals with suspected TSC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous Sclerosis Complex 2 ProteinTuberous SclerosisTuberous Sclerosis Complex 1 ProteinHumansHigh-Throughput Nucleotide SequencingGenetic TestingFemaleMaleMosaicismMutationGenetic Predisposition to DiseaseAdultGenomicsChildAdolescentGenetic Variation

Substanzen

Tuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTSC2 protein, humanTSC1 protein, human

Autor:innen und Institutionen

  • Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK.
  • Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.
  • Center for Biomics and Department of Cell Biology, Erasmus Medical Center, Rotterdam, Netherlands.
  • The Wales Gene Park, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK.
  • Medical Genetics, ASST Santi Paolo e Carlo, Ospedale San Paolo, Milan, Italy.
  • Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.

ORCID-Profile: Mark Nellist, Laura E Thomas, Wilfred F J van IJcken

Förderung

  • Health and Care Research Wales
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • TS Association UK
  • TS Alliance
  • TSC Fonds
  • Michelle Foundation

Zitieren

APA

West, H. D., Nellist, M., Brouwer, R. W. W., van den Hout-van Vroonhoven, M. C. G. N., de Almeida, L. G. D., Hendriks, F., Elfferich, P., Raja, M., Giles, P., Alfano, R. M., Peron, A., Sznajer, Y., De Waele, L., Jansen, A., Koopmans, M., Kievit, A., Farach, L. S., Northrup, H., Sampson, J. R., …, & van IJcken, W. F. J. (2023). Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal. Human Mutation. https://doi.org/10.1155/2023/4899372

Vancouver

West HD, Nellist M, Brouwer RWW, van den Hout-van Vroonhoven MCGN, de Almeida LGD, Hendriks F, et al. Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal. Human Mutation. 2023. doi:10.1155/2023/4899372

BibTeX
@article{West2023,
  author = {West, Hannah D and Nellist, Mark and Brouwer, Rutger W W and van den Hout-van Vroonhoven, Mirjam C G N and de Almeida, Luiz Gustavo Dufner and Hendriks, Femke and Elfferich, Peter and Raja, Meera and Giles, Peter and Alfano, Rosa M and Peron, Angela and Sznajer, Yves and De Waele, Liesbeth and Jansen, Anna and Koopmans, Marije and Kievit, Anneke and Farach, Laura S and Northrup, Hope and Sampson, Julian R and Thomas, Laura E and van IJcken, Wilfred F J},
  title = {Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal},
  journal = {Human Mutation},
  year = {2023},
  doi = {10.1155/2023/4899372}
}
Kostenlos starten →